Studies have demonstrated that in metastatic NSCLC patients with high PD-L1 expression (≥50%) that lack EGFR or ALK mutation, drugs such as pembrolizumab and atezolizumab could improve PFS for approximately 10.3 months and median OS for 15.5 months [63]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.